Chongqing Genrix Biopharma (688443.SS) – Market Snapshot
- Closing performance: Flat at 0 % during the 24‑hour window ending 04:22 AM Central Europe on Saturday, 24 th.
- Current trading price: CNY 24.11 on the main exchanges.
- Shares outstanding: 375 million.
- Market capitalisation: CNY 8.6 billion.
- Volume over last 24 h: CNY 43.2 million worth of shares changed hands.
- Month‑to‑date change: Down 10.24 % since the end of the previous month.
- 200‑day simple moving average (SMA): CNY 23.91.
- 52‑week range:
- High: CNY 32.82 (01 Dec 2026)
- Low: CNY 20.07 (06 Feb 2026)
Contextual Comparison with Peer Listings
| Ticker | Current price | Market cap | P/E | 24‑hr change |
|---|---|---|---|---|
| Yantai Zhenghai Magnetic M (300224.SZ) | CNY 11.39 | CNY 10.3 bn | 30.26 | Flat |
| Weichai Heavy Machinery (000880.SZ) | CNY 22.23 | CNY 10.2 bn | 34.30 | Flat |
| Greatoo Intelligent Equipm (002031.SZ) | CNY 5.29 | CNH 11.1 bn | – | Flat |
| Googol (301510.SZ) | CNY 27.7 | CNY 10.3 bn | 95.86 | Flat |
| Xgd (300130.SZ) | CNY 18.48 | CNY 10.3 bn | 21.48 | Flat |
Analysis
The flat trading day for Chongqing Genrix Biopharma reflects a period of consolidation after a pronounced month‑end decline of over 10 %. With the current price hovering slightly above the 200‑day SMA, the stock appears to be maintaining a modest upside buffer, yet it remains within the upper quartile of its 52‑week range. The market cap of CNY 8.6 billion positions the company solidly among its peers, though its liquidity is comparatively limited given the 43.2 million CNY volume traded in the last day.
The peer group demonstrates a similar pattern of price stability across the board, with all listed entities recording 0 % movement over the same period. Notably, the price‑to‑earnings ratios vary widely—from a high of 95.86 for Googol to a lower 21.48 for Xgd—suggesting differing valuation narratives within the sector.
Forward‑Looking Perspective
Given the current valuation near the 200‑day SMA and the stock’s placement close to its 52‑week high, there is scope for a rebound if the company delivers on its R&D pipeline and regulatory milestones. Investors should monitor any upcoming earnings releases or product approvals that could shift sentiment. In the meantime, the flat 24‑hour performance signals a period of equilibrium, offering a strategic entry point for those seeking exposure to the Chinese biopharma landscape with a balanced risk profile.